Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03428646 · ClinicalTrials.gov registry record
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A clinical trial of Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 858
- Enrollment target
- 20
- Study locations
NCT03428646: Active study of Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals.
NCT03428646 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 858 participants, above the 368-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (133% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03428646, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 858 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
Primary Outcome
Medical history
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (20)
California
- Regeneron Investigational Site - Fountain Valley
- Regeneron Investigational Site - Laguna Hills
- Regeneron Investigational Site - Loma Linda
- Regeneron Investigational Site - Los Angeles
- Regeneron Investigational Site - Los Angeles
- Regeneron Investigational Site - Manhattan Beach
- Regeneron Investigational Site - Newport Beach
- Regeneron Investigational Site - Oceanside
- Regeneron Investigational Site - Redondo Beach
- Regeneron Investigational Site - Riverside
- Regeneron Investigational Site - Roseville
- Regeneron Investigational Site - San Diego
- Regeneron Investigational Site - Santa Monica
- Regeneron Investigational Site - Thousand Oaks
Florida
- Regeneron Investigational Site - Coral Gables
- Regeneron Investigational Site - Margate
- Regeneron Investigational Site - West Palm Beach
Alabama
- Regeneron Investigational Site - Birmingham
Arizona
- Regeneron Investigational Site - Gilbert
Connecticut
- Regeneron Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 858 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2027-03-30 |
What the registry record for NCT03428646 still lists
NCT03428646 is an observational study that tracks outcomes without assigning an intervention. The registered 858 participants enrollment target is mid-sized for trials with a published cap, above the 368-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (133% higher).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03428646 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03428646 about?
NCT03428646 is a clinical study titled "Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)". A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
What is the current status of trial NCT03428646?
This trial is currently active not recruiting. The enrollment target is 858 participants. The study started on 2018-04-06. Estimated completion is 2027-03-30.
What conditions does trial NCT03428646 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03428646?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03428646?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03428646 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03428646's enrollment target sits among peer trials
858 4th of 29 higher than 26 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI